• AI visibility

Guide · AI search

Can AI search build demand for a medical device before the value analysis committee meets?

Yes, at the start of the process: AI tools now sit where surgeons and nurses first read about a technology, and the hospital’s value analysis committee then asks for the same evidence. What those tools can repeat depends on your peer-reviewed data, your clearance facts and how clearly you state your indications. No study yet measures how often AI answers lead to a device request, so treat what follows as a reasoned case, not a proven channel.

By Underneath Team Guide Updated

The short version

  1. The field is crowded: FDA’s device center authorized 124 novel devices in 2025, says its 2025 annual report (opens in a new tab), and an Emergo by UL count (opens in a new tab) found 3,238 510(k) clearances that year.
  2. Hospitals are under cost pressure: the American Hospital Association (opens in a new tab) reports hospital spending on supplies rose 9.9% in 2025, faster than total expenses (7.5%).
  3. Committees now gatekeep every new product: NCH Healthcare System in Florida told vendors that from August 3, 2026, no new products, trials or samples may enter its hospitals without value analysis approval, with clinical evidence first on its list of criteria.
  4. Clinicians already use AI to read the evidence: OpenEvidence, an AI search tool for doctors, reported 760,000 registered US physicians and about 18 million consultations a month in December 2025, according to Wikipedia’s summary of company figures (opens in a new tab).
  5. One approval is worth years of revenue: Intuitive Surgical’s 2025 annual report (opens in a new tab) says a da Vinci system sells for $0.7 million to $3.1 million, and the company earns $900 to $3,700 in instruments and accessories per procedure.

Who decides whether a hospital buys your device, and what is the account worth?

A clinician champion starts it, a value analysis committee vets it, and supply chain and senior management sign it.

The buying group for a medical device is wider than most marketers assume. A surgeon, interventional cardiologist or nurse leader usually asks for the product. A multidisciplinary value analysis committee then reviews it. NCH Healthcare System’s 2026 vendor letter lists what its committee weighs: clinical evidence and patient outcomes, patient and staff safety, regulatory compliance, operational impact, standardization, total cost of ownership, and contracting. Vendors may not hand products to physicians for evaluation without formal approval.

For capital equipment, more people join. Intuitive Surgical says the purchase of its systems “generally requires the approval of senior management of hospitals, their parent organizations, purchasing groups, and/or government bodies,” and that some sales go through competitive bidding or public tenders. It also notes that integrated delivery networks are “creating larger networks of system users with increasing purchasing power.”

What a won account is worth depends on the business model, and most device makers earn far more after the first sale than at it:

  • Capital plus recurring use. A da Vinci system costs $0.7 million to $3.1 million. Service contracts run $95,000 to $225,000 a year, and each procedure brings $900 to $3,700 in instruments and accessories. Intuitive’s installed base reached about 11,106 systems at the end of 2025, up 12% in a year.
  • Consumables and implants. For disposables and implants, committee approval opens the door to recurring purchases across every surgeon who adopts the product, which is why a single approval can matter for years.

Cost pressure raises the bar. With supply spending up 9.9% in 2025, committees have every reason to ask whether a new device is worth more than what is already on the shelf.

Where do AI tools already appear in a clinician’s evaluation?

Mainly where clinicians read and summarize evidence; nobody has yet measured AI’s role in device requests.

Physicians are heavy AI users. The American Medical Association’s 2026 survey (opens in a new tab) found 81% use AI professionally, and The ASCO Post reports (opens in a new tab) that 39% used it for summarizing medical research in 2026, up from 13% in 2024. That research step is where a clinician forms a view about a new device class.

Clinicians increasingly use AI tools built for them:

  • OpenEvidence. Beyond the 760,000 registered physicians reported in December 2025, the company claims that more than 65% of US physicians use it monthly, research firm Sacra reports (opens in a new tab). That figure is the company’s own and has not been independently checked. Sacra describes its search as running “exclusively through licensed medical content” such as NEJM, JAMA, specialty guidelines and drug labels.
  • General assistants for clinicians. Sacra also notes that OpenAI launched ChatGPT for Clinicians, a free product for verified clinicians, in April 2026.
  • Established references. UpToDate, which serves more than 3 million clinicians, launched an AI product in October 2025, according to the same Sacra profile.

Patients are part of demand too, especially for devices they can ask for by name. In a Rock Health survey reported by HIT Consultant (opens in a new tab), 32% of US adults had used an AI chatbot for health information.

What do clinicians and committees ask AI about a device?

Questions about evidence, comparisons, clearance, cost and alternatives. We wrote the prompts below as illustrations; none was collected from a real clinician or committee.

AskerWhat worries themExample prompt (ours)
SurgeonEvidence“What do published trials show for robotic versus laparoscopic approaches in this procedure?”
InterventionalistComparison“How do the main closure devices for this access site compare in published studies?”
Value analysis leadCost“What is the total cost of ownership of a surgical robot over five years?”
Supply chainAlternatives“Which cleared alternatives exist for this single-use device?”
Any reviewerRegulatory status“Is this device FDA cleared, and for which indications?”
PatientAwareness“Is there a less invasive option for this procedure, and which hospitals near me offer it?”

Two features make device questions different from software questions. Many have a clinical edge, so the answer an assistant gives draws on journals and guidelines rather than vendor marketing. And regulatory status is a hard filter: a device either is or is not cleared for a stated use, and committees check it.

How does an AI answer turn into a purchase order?

Through the clinician who requests the device, the committee that checks the evidence, and the procedures that follow.

As we read the evidence, the path runs like this:

  1. A clinician reads about a technology, often through an evidence tool or assistant that cites journals and guidelines.
  2. The clinician asks the hospital to consider it, which triggers a value analysis request.
  3. The committee checks clinical evidence, safety, regulatory status and total cost, and may approve a trial. At NCH, any request to evaluate a new product “must be coordinated through the Value Analysis committee.”
  4. Contracting follows, often through a purchasing group or integrated delivery network.
  5. Revenue grows with use: instruments per procedure, service contracts, more surgeons adopting.

AI can touch steps 1 and 3. At step 1 it shapes what the clinician believes before your representative calls. At step 3, committee members may use the same tools to check claims. We infer that a device whose evidence is published, indexed and clearly summarized is easier to champion and easier to approve; no study has tested this.

There is a limit you must respect. FDA’s final guidance of January 7, 2025 on scientific information on unapproved uses (opens in a new tab) sets out how firms may share such information with health care providers, and Hall Render notes (opens in a new tab) that it requires communications to be truthful and non-misleading. GEO work for a device maker has to stay within your cleared or approved indications and your regulatory team’s review. Drugmakers work under a similar line, covered in keeping drug brands accurate in AI answers.

What decides whether AI tools cite your device’s evidence?

The tools disclose little; analysts describe clinician tools reading licensed literature, and committees ask for independent proof.

Described by the tools or analysts. Sacra’s description of OpenEvidence says it answers from licensed journals, guidelines and labels, with inline citations. General assistants such as ChatGPT and Google’s AI features run web searches and show source links, but none explains why one device is named over another.

Observed in studies. When our hidden-searches study logged ChatGPT’s background queries, it looked for reviews in 46.2% of its answers and ran a search aimed at a named publication, ranking or award in 43.8%. In medical devices, the equivalent of a named publication is a peer-reviewed journal, a society guideline or a respected trade outlet. For consumer health questions, our summary of what ChatGPT-cited health sites have in common shows institutions dominate the citations.

What committees check. These trust factors are specific to devices:

  • Independent clinical evidence. Intuitive says it seeks to show outcomes “validated by rigorous, independent, and peer-reviewed evidence.” Committees want the same.
  • Regulatory facts. Clearance or approval type, indications and any recalls. FDA classifies devices by risk, and Class III devices generally need premarket approval, so the pathway itself signals the level of evidence behind a product.
  • Cost and operations. Total cost of ownership, training, service and how the device fits existing workflows.
  • Peer adoption. Which comparable hospitals use the device and what they report.

Our inference. An AI tool can only repeat the evidence it can find. If your trial results sit in a PDF behind a form, or your indications differ between your website, your instructions for use and distributor listings, assistants have little reliable material to work with. A reasonable expectation is that clear, consistent and independently published evidence gives both clinicians and AI tools more to cite.

What does it cost a device maker to be absent from these answers?

Mostly lost requests and slower committee approvals; nobody has measured the loss directly.

  • No champion, no request. A clinician who never meets your technology in the evidence they read is unlikely to start a committee request. We infer this from the request-led process hospitals like NCH describe.
  • A competitor’s evidence frames the category. If AI answers summarize a rival’s trials and not yours, the committee may begin from their framing.
  • Errors spread. An assistant that misstates an indication or cites an outdated study can create a compliance problem as well as a sales one; see how to fix wrong brand information in AI answers.
  • Answers change. In our consistency study, only 25.2% of the brands ChatGPT named for a question appeared in all five runs, so one good answer proves little.

How does GEO work for a medical device company?

By making accurate, on-label evidence and device facts easy for AI tools to find and cite. Nothing guarantees a mention.

  1. One consistent identity for each device. Use the same device name, clearance type and indications on your website, product pages, distributor listings and press materials. Keep them aligned with your labeling.
  2. Evidence in the places AI tools read. Publish trials and real-world studies in peer-reviewed journals, support registry participation, and help societies and guideline authors find your data. Clinician tools that answer from licensed literature cannot cite what was never published.
  3. Public, plain-language evidence summaries. Give each study a readable page with methods, population, outcomes and limitations, linked to the journal version. Committees and assistants both benefit.
  4. Committee-ready facts. Publish what value analysis teams check first: regulatory status, cost and training considerations, and service terms, where commercial policy allows.
  5. Earned coverage. Clinical trade press, conference presentations and independent reviews are the kind of sources studies associate with AI citations; how brands build authority for AI search covers the method.
  6. Keep paid and earned apart. OpenEvidence is funded by pharmaceutical and device advertising, Sacra reports. Ads may reach clinicians, but they are not the same as being cited in an answer; our piece on whether AI search ads should be labeled explains why that line matters.
  7. Monitor general and clinician assistants. Ask your buyers’ questions repeatedly in ChatGPT, Gemini, Perplexity, Copilot, Claude and Google’s AI answers, and in clinician tools your teams can access; how many prompts to track covers the sample size.

Every piece should pass medical, legal and regulatory review, as your promotional materials already do. Shortcuts such as planted reviews are a serious risk in a regulated field; see legitimate GEO versus manipulation. For the software side of hospital purchasing, see our guide for healthcare software companies. Sellers of hospital equipment bought through quote requests can turn to winning hospital RFQs through AI answers.

What is still unknown about AI search and device adoption?

The link from AI answers to device requests and approvals has not been measured anywhere.

  • No data on value analysis committees and AI. We found no survey asking committee members whether they use AI tools to check evidence.
  • Clinician tool figures come from the vendors. OpenEvidence’s usage numbers are company-reported, summarized by Sacra and Wikipedia.
  • Clinician tools are changing fast. ChatGPT for Clinicians launched in April 2026, and how it chooses sources is not public.
  • One hospital’s letter is not a census. NCH’s rules show how strict committees can be, not how every hospital works.
  • Revenue effects are unproven. See does AI visibility drive business results for the general evidence.

Where should a medical device company begin?

Check what clinicians and committees would read about your device today, then fix the gaps in evidence and facts.

Write down the questions a clinician champion, a value analysis lead and a supply chain manager would ask about your category, plus the questions patients ask about the procedure. Ask each in more than one assistant and repeat it on another day, because one answer is a sample, not a verdict on your device. Record whether your device is named, whether its clearance and indications are stated correctly, and which studies are cited, yours or a competitor’s.

To go further, ask us to review how AI tools present your device to clinicians and committees. The review shows where answers misstate your clearance or skip your evidence, and which published proof would most help your clinician champions get product requests through value analysis and into procedures. Every piece of the ongoing evidence and device-fact work stays on-label and goes through your regulatory review, as our generative engine optimization service page explains.

Frequently asked questions

Do surgeons use AI tools to research new devices?

No study measures device research specifically. Physicians broadly use AI: 81% do so professionally, and 39% use it to summarize medical research.

Can we promote off-label uses through AI-friendly content?

No. FDA’s January 2025 guidance governs how firms share information on unapproved uses with providers. Keep content within your indications and regulatory review.

Does advertising on clinician AI tools get our device cited?

There is no public evidence that it does. Ads and answer citations are separate, and clinician tools describe answering from licensed literature.

Which matters more for AI visibility, our website or journal publications?

For clinician tools, published evidence, since they describe answering from licensed journals and guidelines. Your website still matters for clear device facts.

How long before GEO affects device sales?

Expect a long horizon. Capital contracting cycles are lengthy, committees meet on schedules, and evidence takes time to publish.

Sources

Free strategy call

Some questions are easier to answer about your own business.

Bring the one that matters most. On a free 30-minute call we’ll take a first look at it and send you a short written read afterward.

Ask about my businessHow we work